WuXi Biologics (Cayman) Inc. (HKG:2269)
Hong Kong · Delayed Price · Currency is HKD 33.40
-0.20 (-0.60%)
Jul 30, 2025, 4:08 PM HKT
WuXi Biologics Employees
WuXi Biologics had 12,575 employees as of December 31, 2024. The number of employees decreased by 165 or -1.30% compared to the previous year.
Employees
12,575
Change (1Y)
-165
Growth (1Y)
-1.30%
Revenue / Employee
1.58M HKD
Profits / Employee
284.01K HKD
Market Cap
135.91B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 12,575 | -165 | -1.30% |
| Dec 31, 2023 | 12,740 | 367 | 2.97% |
| Dec 31, 2022 | 12,373 | 2,509 | 25.44% |
| Dec 31, 2021 | 9,864 | 3,218 | 48.42% |
| Dec 31, 2020 | 6,646 | 980 | 17.30% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| BeOne Medicines | 11,000 |
| Hansoh Pharmaceutical Group Company | 8,989 |
| JD Health International | 3,564 |
| Innovent Biologics | 5,659 |
| Akeso | 3,035 |
| Sino Biopharmaceutical | 24,379 |
| CSPC Pharmaceutical Group | 21,400 |
| Sichuan Kelun-Biotech Biopharmaceutical | 1,837 |
WuXi Biologics News
- 14 days ago - WuXi Biologics Granted Highest Negligible-Risk ESG Rating from Morningstar Sustainalytics - PRNewsWire
- 4 weeks ago - WuXi Biologics Launches Next-Generation Platform WuXiHigh™2.0 for High-Concentration Biologics with Protein Concentration Reaching 230 mg/mL - PRNewsWire
- 6 weeks ago - Focus: China pharma projects disrupted by Sino-US tensions - Reuters
- 6 weeks ago - Hong Kong stocks waver on China’s mixed economic data - South China Morning Post
- 7 weeks ago - WuXi Biologics Kicks off Construction of Microbial Manufacturing Site for Commercial Production in Chengdu - PRNewsWire
- 2 months ago - Hong Kong stocks jump as US blocks Trump’s tariffs in win for global trade - South China Morning Post
- 2 months ago - WuXi Biologics: Eyes On Long-Term Risks And Near-Term Outlook (Rating Downgrade) - Seeking Alpha
- 2 months ago - WuXi Biologics Congratulates Partner CANbridge Pharmaceuticals on the Approval of Innovative Velaglucerase-beta for Injection (Gaurunning) for Gaucher Disease by China NMPA - PRNewsWire